Waters (NYSE:WAT – Get Free Report) and MindWalk (NASDAQ:HYFT – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.
Institutional and Insider Ownership
94.0% of Waters shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 0.3% of Waters shares are owned by insiders. Comparatively, 6.8% of MindWalk shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Waters and MindWalk, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Waters | 0 | 7 | 16 | 1 | 2.75 |
| MindWalk | 1 | 1 | 2 | 1 | 2.60 |
Waters currently has a consensus price target of $457.50, suggesting a potential downside of 0.85%. MindWalk has a consensus price target of $5.00, suggesting a potential upside of 342.48%. Given MindWalk’s higher probable upside, analysts clearly believe MindWalk is more favorable than Waters.
Earnings & Valuation
This table compares Waters and MindWalk”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Waters | $4.64 billion | 9.76 | $642.63 million | $4.01 | 115.07 |
| MindWalk | $16.23 million | 3.25 | -$10.11 million | ($0.26) | -4.35 |
Waters has higher revenue and earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Waters has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, MindWalk has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.
Profitability
This table compares Waters and MindWalk’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Waters | 3.58% | 11.27% | 6.73% |
| MindWalk | -105.11% | -133.26% | -77.78% |
Summary
Waters beats MindWalk on 12 of the 14 factors compared between the two stocks.
About Waters
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
About MindWalk
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.
